Hello and welcome everyone to our presentation of our Q1 report. I know that we're going into a long weekend here in Sweden. So, really appreciate everyone taking the time to join us.
I'll start off with the usual disclaimer here.
We'll take this as read and understood.
So we'll go through the fairly regular agenda we've done on these.
I'll give you some of the commercial updates here. I'll speak to our recent FDA clearance and what that means for us in the market and for our customers. And then I'll spend a little bit of time on our priorities for the remainder of the year before handing over to Christer to go through the financials and obviously the Q and A at the end.
So with that, and for those who don't have very much time with us today, some highlight messages I would want you to take away from this presentation.
The first point is that Q1 of this year was thus far a record one for moving instruments into the market. We put seven instruments out there. I'll talk more to that.
We also saw our highest demand yet for consumables.
This is, notwithstanding an approval that came during April for the FDA clearance. So this is our big news for this month. It materially expands our value proposition for US customers. I'll speak to that.
We think this will make a very real difference in the market over the coming months and quarters. And with that, we do expect the US market to jump-start following this approval. I'll speak to the pipeline we're working with and the dynamics there. Then we have a little bit of an update on our R&D side. We expect to be able to launch our dedicated Isolate kit during Q3 of this year under Research Use Only (RUO) registration. And I'll speak to the background of this one and what the opportunity is, but we're very excited for that news coming to the market back half of this year. And then finally, as Christer will speak to in more detail, we have been successful in executing on our restructuring and cost management activities. So we now see our OpEx dipping below 11 million SEK per month with a favorable trend line in that regard.
So with that, for those new to these presentations and Q-linea AB, firstly, welcome. And secondly, just a quick overview of what we do. So we are a medical diagnostics company focused on the bloodstream infection and high antibiotic resistance challenge in the world. To resolve this, we provide an integrated solution that's built around a diagnostic instrument called the ASTar and its associated menu that I'll speak to in more detail during this call.
And it has a few unique features amongst many, but a few that really stand out in terms of making it unique on the market. It is the only fully-automated, random access platform on the market, available worldwide, including the US and Europe. It is a very easy to use system, with limited hands-on time in the lab. This is much appreciated.
I will speak more to what we're hearing from the market there, and it provides a test in a quick turnaround time vis-à-vis current Standard of Care, saving upwards of 30 hours to wait for the test.
As you always know, when you run an ASTar test, it will be ready in six hours. So that's what we do and what we're trying to achieve in aggregate here with our business plan. And our objective is to really deliver for patients with acute infections, which originate as bloodstream infections. Patients either have sepsis or are at a serious risk of acquiring it. Right now, these are treated by standard of care that will deliver an answer typically 36 to 72 hours after the blood culture goes positive. And our mission is to convert this to a same-day result, providing the answer in six hours from positivity.
As I said, we start with blood infection. There are 5 to 7 million of those in our addressable markets. But I will speak more in today's presentation on going beyond blood and what that means. So I think what we're all interested to hear more about is how do we see the commercial pipeline progressing?
I would start by just stating that obviously the US market really gets going now with our V2 menu approval. Our pipeline of evaluations and customers waiting. This has been building up in the background. So you see that kind of in the increasing number of evaluations shown in the graph here, as the US activity starts to pick up pace in expectation of this.
And now our focus is on converting that pipeline in the US.
Meanwhile, the rest of the world has continued steadily. Italy remains the leading market. We have shipped during this month a few more, or signed a few more contracts, and we shipped some instruments during Q1 as well for contracts that were signed before the new year. But three new contracts have recently been signed. So Italy is on pace.
We have also signed our first contract in the DACH region in Austria. We're excited about that. We see a positive outlook for the rest of this year and certainly going into next year as that region comes on stream for Rapid AST. We are excited about our first close in the southeastern United States on the back of V one. So that is already in place.
The team there is trained; it's going live. Right now, with real patients. So we will see the effect of that through Q2 and going forward this year. And then obviously, as I said, for the remainder of this year, it's about really pushing on the conversions for the rest of the US customers that have been waiting for this approval.
So in the background, once we sign the contract, then there's effort made to work with the site to receive the shipment and do the installation and training that typically takes one month at its fastest, up to two or three months. So there's a bit of a lag, and you see the ASTars in use sort of ticking up in the background. That would be expected to track closely to the contracted ASTar over time. Then, once we go into clinical use, we see the pull through in the tests, and the trend line is visible there as well.
So, I think the macro story here is that the European market is continuing on the plan that we outlined at the beginning of the year. And the US market is sort of. Now off to the races with the approval that has been received.
More or less right when expected. In fact, the FDA was a few days faster. For us than anticipated.
So I'll speak a little bit more to that in detail.
This gets a little bit into the weeds of sort of what we do. So I'll give a little. Bit of orientation. What you're seeing on this slide is a graphic that's essentially the menu that a physician is getting results for.
And each of the dots here represents a drug-bug combination for which the physician wants results. So they know how to treat the patient. The more dots, simply speaking, the more options for the physician. And what we did with this recent clearance was we increased the number of dots on our menu here by 93.
So we now have 215 approved combinations in the US. This is by far the market leader. I'll speak to that in more detail in the next slide. But from a physician perspective, what's also critically important is we've added a number of new drugs that they were really waiting for. Specifically ceftriaxone and ertapenem. If we had to pick on a couple of things, these were the two big ones that were holding back our V1 menu as they are go-to drugs for physicians as they consider their therapy decisions.
And they wanted to have these available before recommending ASTar for the breadth of their patient population. Another key feature that's very relevant for physicians and obviously the labs is that now with this approval, we also have the update to all of the latest FDA breakpoints. I won't go into the details of what that is.
Suffice to say that over time resistance changes in bugs, and that affects the breakpoints. So you want to make sure that you're getting an instrument that has the latest and greatest view on those that the FDA regularly updates.
And now we have that all embedded and approved on the platform as well.
This is a huge step forward for us clinically in terms of value proposition.
Like I said, for customers, we now have the broadest antibiotic and pathogen menu available. We no longer see any major clinical gaps for a physician. Like I said, Ceftriaxone Ertapenem are now there. That gives them more options for therapy decisions. That increases the value of the platform.
It also gives crucially more confidence now to de-escalate to oral therapy. That's where a hospital would see savings. When you have patients that are waiting for one reason or another in an ICU bed, that's very expensive.
They may be holding them or cannot discharge them until they have confirmation of the resistance profile of the medication on which they would like to discharge them.
And now we have more options than any other on the market to provide that.
So what we see now going forward for us is that the pipeline we've been diligently building here in the background will start to converge. I think I've mentioned it before.
We had hopes that the V1 menu would be able to carry us there, especially with the efforts we did on our bridging strategy. We understood some of the clinical limitations. Now that those limitations are gone, there's really no excuses for not deploying.
So we do expect to see a difference here going forward.
And I'll get to this in a second, but we're very confident this makes us the clearly differentiated gold standard platform in the market, both with the clinical side of things with the menu, but also just reinforcing the underlying proposition from ASTar in terms of ease of use. And it's very efficient workflow for the lab. So this is another picture, basically that same menu, but color coded here. And we just wanted to use this as a visualization, again, as if you're a physician or a microbiologist in the lab, you have different tools you can choose from.
And this menu of results is a key factor in selecting those tools. So, what we've done here is we've taken the liberty of overlaying the ASTar menu on top of what would be the next best system you could buy in the market in the US. Anything orange on this picture is exclusive to ASTar, and anything blue is not available on our platform.
I'll talk a little bit more on that in a second, but just right there, you can see that there's a lot, a lot of orange. So this makes it clearly a standout differentiator, and for clarity, all the gray boxes shown here are available on both platforms being assessed. I'll call out a couple of things. First of all, you'll see some stars on the combinations.
Not all drug-bug combinations are created equal; for each type of pathogen, you have typically recommended therapies for either empiric treatment, escalation, or de-escalation.
So part of the trick here is to map our offering to how hospitals really use the drugs in their clinical setting.
We've done a lot of work to understand that and how that differentiates or differs between markets. The US is different than Europe in terms of how it applies it, and similarly for the world as a whole. And we have now a very strong US specific offering. And the stars here indicate many of those combinations that we have that are certainly not available on the second best, and in most cases are not available on any platform on the market other than ASTar.
We think this creates a very standout offering just on the surface, but then it gets even better: the ASTar platform, built with its disk of 336 wells, allows us to provide a lot more dilution steps per drug. And it allows you to provide what we call the MIC value, which is the specific result at that dilution step. And it allows you to provide the, we call it the MIC value, but the specific result at that dilution step. And if you do not have as many steps, you're forced to make some compromises.
Either you skip some, and your system is interpolating or extrapolating the findings, which isn't a true MIC. And this is never the case for an ASTar. You are always getting a true MIC, or in the worst cases, for other platforms that don't have the necessary number of dilution steps.
When the breakpoints change, it means they can drift out of the dilution range that you have available, and that really changes or decreases the clinical value of the result.
So, just reinforcing again our advantage: as the FDA breakpoints were updated in this latest round, we were readily able to update the system with all of those because we always have all of the dilution steps.
So, this is, as I keep saying, a huge step forward for us. It makes us very clearly the leader here, and those with observant eyes will notice a couple of blue lines where there are drugs. We don't have one of them. Imipenem has been, by and large, replaced by other carbapenems here on our menu. So we're not at all worried about that.
There's no stars there. That doesn't come up in physician conversations.
The other Amoxiclav we actually have on our disk is the European formulation. We're working to add the US formulation.
There will of course be some labs that would maybe look to our results using our advanced user software just to validate other forms of testing on the Amoxiclav.
So there is still some value from what we have there.
We're not worried that this is in any way a showstopper. In that regard, there's plenty of alternate information available on our platform for any physician. So, we obviously make a lot of claims ourselves, but we are particularly excited when the customers make statements themselves. Right.
And we were particularly proud and happy for the team at Baylor, Scott & White when they were recognized by Microbiology Spectrum, a leading journal in the microbiology space for their pioneering work in rapid AST.
The team has been an early adopter with us. We've worked very closely, and it's been fantastic to see them putting the ASTar into clinical use. And now we've had some time in hand, so to speak, with the instrument.
And we're starting to see the data coming out from that.
And they were able to put this into a journal that was accepted. So a big congratulations to that team.
I would say the results are not overly surprising for those who have been following us before. They are confirmatory to what we've seen before. Obviously, the performance of the ASTar is very high and always nice to see that on true clinical isolates; the study differentiates them between real-life patients and those pulled from data banks or biobanks.
So the real-life clinical performance is very high for ASTar.
We see the same results over and over and over every time we do these significantly faster test results than standard of care. Here we saw savings of over 30 hours. And this can be life changing for a patient and obviously has very positive economic benefits to the hospital as well.
It is very interesting to see this data.
And there was more breakdown for those who have a chance to read it in terms of the therapy recommendations that would have been made on the ASTar results, would have influenced around here, 83% of cases, which is, I would say higher than sometimes we see, sometimes we see, you know, 75 or so percent. So here, obviously, these patients benefiting from the more accurate results that ASTar can provide faster, in roughly two thirds of the cases, would have been able to de-escalate the patient off of broad-spectrum or aggressive treatment onto something that would have less toxicological damage for the patient, and obviously reducing the exposure and long-term resistance impact from overusing our last resort drugs.
Or you could say, our aggressive drugs. And very importantly, in 14% of the cases, patients would have been escalated. And this is very meaningful because that means the empiric therapy they were receiving would not likely have yielded as good results clinically. So possibly life-saving.
Right. And in addition to all of that impact on the patient, which we're very pleased to see. The report also highlights many of the downstream benefits that we would expect to see from adopting rapid AST.
Obviously, the benefits I mentioned, such as reducing overall antibiotic exposure, being able to discharge the patient earlier, as I talked about before, and overall reducing the length of stay. So again, these are really tangible clinical and in-hospital benefits that are seen when ASTar is adopted.
So, very, very happy to see that Baylor, Scott & White is finding that and Microbiology Spectrum was open to putting that into publication. And on that note, we've not stayed still in terms of the value proposition; from the outset, we've been aiming to provide a comprehensive solution for improving treatment of patients with infectious disease. And as part of that, obviously, the blood infection patients were the number one place to start, being the most critically urgent. Call it a high-value patient, if you will, but not losing sight of the fact that there are many other patients in the hospital that could benefit from a faster result.
So we have long had an idea to develop a non-blood kit. And now we're very proud to say that we have visibility now on launching this under Research Use Only application during Q3 of 2026. And in advance of that, a couple customer posters. We highlight Baylor, Scott & White again as an active user.
We were very happy that they were open to exploring the research application here with us with very positive results. And excited also that an Italian customer, an active customer of ASTar, also saw similar results, both pointing to the fact that ASTar is reliable and shows very high performance in clinic when isolate tests are applied.
And we did our own very aggressive testing with some of the most gnarly resistance bugs we could get our hands on. And our poster that was also presented just highlights that the performance stays high with ASTar. So it is a very robust system.
I think the other thing to highlight that the Baylor, Scott & White paper points out is that the workflow for ASTar is extremely easy, because everything is done on the system for the blood test. It basically doesn't change. So you can go essentially straight from the plate in the lab where you're culturing the isolate straight into ASTar with no intermediate steps. And this can sometimes be a barrier for hospitals in doing a rapid test off of this, because of the workflow challenges for other platforms. So it just again, it further doubles down on ASTar ease of use that was designed really for this type of application in mind downstream.
So we're excited to see this, obviously for the research customers initially here.
Timing of a full clinical product will be a little bit contingent on feedback from the market. But we should see some effects from this already from RUO launch. Hopefully during this year and through early next year.
So before I close out, just to kind of recap our short-term priorities, we remain ultra-focused on that commercial pipeline. The drive, as I keep saying, on those US customers, they've been standing there waiting enthusiastically in line. So you can bet the team is on calls with them all the time now, planning timelines; just to set expectations, obviously there are many steps involved, including contracting and legal processes in many cases, and so on. So these are large institutions. This will not happen overnight, but we will be working on the backlog and getting instruments out as soon as we can.
So the other things we're doing, we do see that the Italian footprint continues to expand at a pretty predictable pace here, converting the pipeline we see in Italy. What we're really working on now is to take the positive feedback that we get from the physicians and the lab, and to turn that into more tests. The Italians are very open that due to economic reasons, basically budget constraints, they have to ration which patients get rapid AST. And they know that's not an ideal situation, but it's when you're adopting a new technology that it's often the case. So what we're doing now is to work with them to highlight the impact that they are seeing in their clinics and to help manage their stakeholders to increase testing over time. This will not be something that is a major step change overnight, but we already see positive trends month on month, and we get more and more advocates in our corner. And I will continue to point to Italy as the bellwether for what to expect from rapid AST.
They remain in the lead here. So, it's very good to see that trend.
We will continue to work on that.
And now the team is active. Franco is working diligently on expanding our footprint.
On previous calls, I've said we've wanted to remain very focused, conscious of resources. Now is a good time. We have completed the US launch, and we can now focus on the next step, which is adding the next tranche of geographies to our distribution set.
I would point out that the ESCMID conference that was held here in April in Munich was very energizing. I had a chance to talk to dozens; in total, we spoke with 100 plus customers, distributors, and so on. And I interacted with many of the distributors there. And very encouraging to see that not only is rapid AST seen as a solution for critical AMR challenges around the world, we knew that, but now ASTar is really standing out as the platform that distributors want to work with and to bring it in. They're coming to us with specific customer deals or lead flagship customers in their markets that they want to introduce ASTar to and start working on. So this is the work that we have been working a little in the background, and now we really double down and get that going. And on the clinical side, I've previously discussed the non-blood testing, particularly the isolate testing kit. So work pivots to getting that on market now, as well as the next phase, which is to add more drugs. Fortunately for patients around the world, pharmaceutical companies are not standing still. They know resistance is increasing on existing therapies. We need another. The next line of defense against infection.
We will keep pace with them. I would say one key advantage here now is that, being seen as the gold standard in this field, the pharma companies are very open to working with us actively. So several of them have already provided us with active ingredient to work with, with guidance on how to support our formulation and, crucially, with help characterizing bacterial strains so that our algorithm work goes even faster, which reduces costs and time for us to get new things on the market and has a positive effect for them when the leading diagnostic instrument can give a readout on the relevance of their new therapy vis-à-vis existing therapies. A powerful, mutual benefit for all parties, including the patient. And then, not losing sight of our continued cost-down activities. We do that also for OPEX. Krista will speak more to that, but the team is paying a lot of attention on our CoGS as we see the scale growing in consumables. I've talked many times that we have a set of activities we will trigger at each volume milestone, and we look to achieve those milestones and set up to realize them. So CoGS continues to come down against plan. And now with the instrument shipments growing, like I said, seven in Q1, the CoGS in the instrument becomes more and more relevant. So activities happening there as well.
And I won't step too much on Krista's points on the financial side, so I'll turn it over to him. But just suffice to say that we're very happy to see that we're on plan here, trending down below 11 as we guided to before. And one of the things that I'm focused on here in the commercial side is that we maintain as good a capital recovery profile as we can. Obviously, we know many customers will want to place the instrument on reagent rental.
That's fine. It's part of the business model in our area. We expect it. We plan for it.
It's a good model for us as well.
That said, it does require more capital from us as the instrument is out and it takes more time for the money to come in.
So the balance of this is key, making sure that we're working with customers where they have the balance sheet to use that to mutual benefit, to allow our cash runway to go as long as possible.
So that's another big area of focus for myself and the commercial team and obviously Krista as well. So with that, I'll turn it over to you.